Combining biology with technological solutions will lead to medical progress. However, extensive efforts are required to bridge the gap between discovery, invention and application.
Simon Hoestrup is part-time professor at the department of Biomedical Engineering (research group Soft Tissue Engineering and Mechanobiology). He is Chair and Director of the Institute for Regenerative Medicine (University Zurich) and Founding Co-Director of the Wyss Zurich (University Zurich & ETH Zurich) in Switzerland. His work at the interface of basic science and translational research has resulted in more than 150 peer-reviewed scientific publications and a unique patent portfolio in the field of Regenerative Medicine. Hoerstrup leads several major scientific international consortia projects funded by the European Commission, the Swiss National Science Foundation, Commission for Technology and Innovation, etc.
Simon P. Hoerstrup studied medicine at the University of Cologne with electives in Switzerland (University of Berne) and the USA (Baylor College of Medicine and Texas Heart Institute, Houston; Harvard Medical School, Boston). After graduation in 1995, he received his Medical Doctor (M.D.) degree (magna cum laude) from the University of Cologne and started his clinical education in Cardiovascular Surgery at the University Hospital Zürich, Switzerland. From 1998-2000, he received a research grant of the German Research Foundation and Harvard Medical School to become research fellow at Children’s Hospital Boston, Harvard Medical School. In 2001, he received his 'Habilitation' (Privatdozent Dr. med.) from the Medical Faculty of the University of Zürich, Switzerland. In 2003, he was appointed part-time professor at the department of Biomedical Engineering of Eindhoven University of Technology (TU/e). Currently, he is Chair and Director of the Institute for Regenerative Medicine (University Zurich) and Founding Co-Director of the Wyss Zurich (University Zurich & ETH Zurich) in Switzerland. He also is Associate Member of the Department of Health Science Technology at the Swiss Federal Institute of Technology (ETH) and associate faculty of the Harvard Wyss Institute for Biologically Inspired Engineering in Boston (USA). Furthermore, Hoerstrup is co-founder of a series of medtech and biotech spin-off companies (Symetis AG, Xeltis AG, Insphero AG, etc.).
Computational modeling guides tissue-engineered heart valve design for long-term in vivo performance in a translational sheep modelScience Translational Medicine (2018)
Puncturing of lyophilized tissue engineered vascular matrices enhances the efficiency of their recellularizationActa Biomaterialia (2018)
The future of heart valve replacementJournal of Tissue Engineering and Regenerative Medicine (2018)
Are adipose-derived stem cells cultivated in human platelet lysate suitable for heart valve tissue engineering?Journal of Tissue Engineering and Regenerative Medicine (2017)
In situ heart valve tissue engineering using a bioresorbable elastomeric implant - From material design to 12 months follow-up in sheepBiomaterials (2017)
- Head Tissue Engineering Division, Department of Surgical Research, University Hospital Zurich, Zwitserland
- Member board of Principal investigators, University Hospital Zurich, Zwitserland, Center for Clinical Research
- Associate member, Swiss Biotechnet, Zwitserland
- Co-founder and member of the scientific board, Symetis AG, Zurich, Zwitserland
- Shareholder, Xeltis BV